This observational cross-sectional study aims to investigate the effects of glycemic control and clinical parameters on tibial nerve conduction latency in individuals with diabetic peripheral neuropathy. Adults aged 45 to 76 years with diabetic peripheral neuropathy will be evaluated at a neurology and clinical neurophysiology clinic.
Data collection will include demographic and clinical characteristics, diabetes type and duration, fasting blood glucose, and HbA1c values obtained from routine clinical records. Participants will also be assessed using the Michigan Neuropathy Screening Instrument (MNSI), including both the questionnaire and physical examination components. Nerve conduction studies will be performed using standard electromyography procedures, and tibial nerve conduction latency will be recorded.
The study will examine the relationship between tibial nerve conduction latency and glycemic control parameters, neuropathy screening scores, and diabetes duration. The findings may help improve early identification and clinical evaluation of diabetic peripheral neuropathy.
Eligibility
Sex
ALL
Min age
45 Years
Max age
76 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants aged 45 to 76 years
* Diagnosis of diabetes-related neuropathy based on laboratory tests, clinical findings, and nerve conduction test (NCT) results
Exclusion Criteria:
* History of autoimmune disease, cerebrovascular disease, or chronic infectious disease
* Diagnosis of cancer or a history of chemotherapy and/or radiotherapy
* Radicular neuropathy
* Chronic kidney failure or liver failure
* Alcoholism or other substance dependence
* Mental or physical disability (including blindness)
* Inability to speak Turkish
Primary outcome measure(s)
Tibial Nerve Conduction Latency — At baseline Tibial nerve conduction latency measured by standard nerve conduction study/electromyography procedures in individuals with diabetic peripheral neuropathy. The study will evaluate its relationship with glycemic control parameters, Michigan Neuropathy Screening Instrument scores, and diabetes duration.
Michigan Neuropathy Screening Instrument Questionnaire Score — At baseline The Michigan Neuropathy Screening Instrument (MNSI) Questionnaire is a participant-reported measure used to assess neuropathic symptoms in individuals with diabetic peripheral neuropathy. The questionnaire consists of 15 yes/no items. Responses are scored according to the standard MNSI scoring approach, and the total score is calculated by summing the scored items. In this study, a score of 4 or higher will be interpreted as indicating neuropathic symptom involvement. Higher scores indicate a greater burden of neuropathic symptoms, whereas lower scores indicate fewer reported neuropathic symptoms. The questionnaire score will be analyzed in relation to tibial nerve conduction latency.
Michigan Neuropathy Screening Instrument Examination Score — At baseline The Michigan Neuropathy Screening Instrument (MNSI) Examination is a researcher-administered clinical assessment used to evaluate signs of diabetic peripheral neuropathy. The examination includes assessment of vibration sensation, ankle reflexes, and the presence of foot ulceration or deformity. Each examination component is scored according to predefined criteria, and the total score is calculated on an 8-point scale. In this study, a total score of 2.5 or higher will be considered abnormal. Higher scores indicate more severe clinical findings consistent with peripheral neuropathy, whereas lower scores indicate fewer abnormal examination findings. The examination score will be analyzed in relation to tibial nerve conduction latency.
Hemoglobin A1c (HbA1c) — At baseline HbA1c value obtained from routine clinical laboratory records as an indicator of glycemic control.
Fasting Blood Glucose — At baseline Fasting blood glucose value obtained from routine clinical laboratory records.
Diabetes Duration — At baseline Duration of diabetes recorded from clinical history and patient records.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.